|
Transgene is a fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases. Our expertise covers all stages of product development, from research to the manufacture of clinical batches, and the conducting of clinical trials.
Four products are currently in clinical development: TG4010 having completed phase II trials, TG4001/RG3484 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial.
Transgene has concluded strategic agreements with two major pharmaceutical companies... >>> READ MORE |
September 1, 2010
Transgene Receives Positive Scientific Advice from the European Medicines Agency for the Phase IIb/III trial
September 1, 2010
Transgene Reports First Half 2010 Results In Line with Expectations
July 12, 2010
Transgene Announces Opening of First Clinical Site for its
Phase II Trial of TG4040 for the Treatment of Chronic
Hepatitis C
|
Products
Cancers
   Infectious diseases
  |
PUBLICATIONS
|